Prothena Corporation plc Stock News

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

Prothena (PRTA) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.78 per share a year ago.

Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.

Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.

Prothena Corporation plc (NASDAQ:PRTA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Eric Endicott - Senior Vice President, Corporate Affairs and Communications G

Upgrades For Plexus Corp (NASDAQ:PLXS), Sidoti & Co. upgraded the previous rating of Neutral to Buy. For the first quarter, Plexus had an EPS of $1.49, compared to year-ago quarter EPS of $0.88. The c

Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.

Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.

Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 1 0 0 Last 3

Cantor Fitzgerald has decided to maintain its Overweight rating of Prothena Corp (NASDAQ:PRTA) and raise its price target from $91.00 to $98.00. Shares of Prothena Corp are trading up 1.36% over the l

Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by some 8.35% to $57.95 during Tuesday's after-hours session. The company announced that it has commenced an underwritten public offeri

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.

Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.

Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.

Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled. The post Roche's Alzheimer's Drug Fails In Phase 3; Here's The